Found 6801 clinical trials
Customer Outcomes & Value Experiencing A New Monitoring Technology
To investigate whether novel insight features in new Blood Glucose Monitoring System (BGMs) can improve glycemic control.
- 0 views
- 19 Feb, 2024
- 2 locations
Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes
This study will evaluate the effects of 3 intra-nodal injections of GAD-alum (Diamyd), together with oral vitamin D supplementation. Safety and feasibility of the treatment will be evaluated and also effects on the immune system and on the preservation of endogenous insulin production.
- 0 views
- 19 Feb, 2024
- 2 locations
Cardiometabolic Effects of Rapid Glucose Excursion
The effects of rapid glucose excursions, induced by intravenous bolus application of glucose in healthy probands, on cardiometabolic and inflammatory parameters will be investigated
- 0 views
- 19 Feb, 2024
- 1 location
Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects
The objective of this early feasibility study is to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic control in type 2 diabetes subjects.
- 0 views
- 19 Feb, 2024
- 5 locations
At-Risk for Type 1 Diabetes Extension Study
This study is an extension of the NIH-sponsored AT-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who develop clinical type 1 diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment within one year of diagnosis of …
- 0 views
- 19 Feb, 2024
- 5 locations
Internet Intervention for Diabetes Distress.
This study is designed to investigate the potential effectiveness of an internet-delivered intervention for diabetes distress in patients with type 2 diabetes.
- 0 views
- 20 Jun, 2025
- 19 locations
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney.
- 0 views
- 19 Feb, 2024
- 2 locations
Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)
The work proposed pushes the limits of these challenges by providing evidence, identified by a team-based approach to glucose management in an underserved and understudied population supplementing prior data designed to improve outcomes among high-risk patients with type 2 diabetes (T2D) and related cardio metabolic conditions. The proposed intervention is …
- 0 views
- 19 Feb, 2024
- 1 location
Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients
Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes or pre-diabetes. The main objective is to measure the cumulative incidence of diabetes and pre-diabetes 6 months after TIPS insertion.
- 0 views
- 19 Feb, 2024
- 1 location
UPENN Case Test Trial 2 (Do Not Make Any Changes)
UPENN Case Test Trial 2 (Do Not Make Any Changes)
- 0 views
- 02 May, 2025
- 1 location